Literature DB >> 18159102

Effectiveness and safety of routine primary angioplasty in patients aged > or =85 years with acute myocardial infarction.

Serafina Valente1, Chiara Lazzeri, Claudia Salvadori, Marco Chiostri, Cristina Giglioli, Serena Poli, Gian Franco Gensini.   

Abstract

BACKGROUND: Although octogenarians constitute a fast growing portion of cardiovascular patients, few data are available on the outcome of very old patients (age >80 years) with ST-segment elevation myocardial infarction (STEMI) undergoing primary angioplasty. METHODS AND
RESULTS: Short- and long-term outcomes of 88 consecutive very old (age > or =85 years) patients with STEMI undergoing primary angioplasty were evaluated. In-hospital mortality was 17%, significantly higher in patients with cardiogenic shock (90%; p<0.001), with failure of percutaneous coronary intervention (PCI; p=0.016), with Killip class > or =III on admission (p=0.018), or with chronic renal failure (p=0.033). Major bleeding complications occurred in 11 patients (12%). Multivariable logistic regression analysis identified 3 independent predictors of in-hospital death: age > or =90 years (p=0.018), Killip > or =III on admission (p=0.018), and PCI failure (p=0.025). Multivariable logistic regression analysis identified age > or =90 years (p=0.008), Killip > or =III on admission (p=0.015), and time from symptoms to PCI >12 h (p=0.04) as independent predictors of mortality at long-term follow-up.
CONCLUSIONS: The low incidence of procedural complications, together with good long term survival, suggest that primary PCI in STEMI patients > or =85 years is safe and efficacious, with a low rate of PCI failure in the presence of a low Killip class on admission, whereas primary PCI is unable to affect the poor prognosis for very old patients with cardiogenic shock.

Entities:  

Mesh:

Year:  2008        PMID: 18159102     DOI: 10.1253/circj.72.67

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  6 in total

1.  Combined therapy with Chinese medicine and percutaneous transradial coronary intervention for a centenarian patient with acute myocardial infarction.

Authors:  Lei Wang; Min-zhou Zhang; Guang Yang
Journal:  Chin J Integr Med       Date:  2009-07-02       Impact factor: 1.978

2.  Prognostic implications of optimal medical therapy in patients undergoing percutaneous coronary intervention for acute coronary syndrome in octogenarians.

Authors:  Atsushi Anzai; Yuichiro Maekawa; Masaki Kodaira; Satoshi Mogi; Takahide Arai; Takashi Kawakami; Hideaki Kanazawa; Kentaro Hayashida; Shinsuke Yuasa; Akio Kawamura; Keiichi Fukuda
Journal:  Heart Vessels       Date:  2014-02-04       Impact factor: 2.037

3.  Predictors of the early outcome in elderly patients with ST elevation myocardial infarction treated with primary angioplasty: a single center experience.

Authors:  Chiara Lazzeri; Serafina Valente; Marco Chiostri; Claudio Picariello; Gian Franco Gensini
Journal:  Intern Emerg Med       Date:  2010-09-18       Impact factor: 3.397

4.  Effectiveness of percutaneous coronary intervention within 12 hours to 28 days of ST-elevation myocardial infarction in a real-world Chinese population.

Authors:  Xingli Wu; Dingyou Yang; Yusheng Zhao; Caiyi Lu; Yu Wang
Journal:  PLoS One       Date:  2013-03-12       Impact factor: 3.240

5.  Temporal trends and in-hospital outcomes of primary percutaneous coronary intervention in nonagenarians with ST-segment elevation myocardial infarction.

Authors:  Joon Young Kim; Myung Ho Jeong; Yong Woo Choi; Yong Keun Ahn; Shung Chull Chae; Seung Ho Hur; Taek Jong Hong; Young Jo Kim; In Whan Seong; In Ho Chae; Myeong Chan Cho; Jung Han Yoon; Ki Bae Seung
Journal:  Korean J Intern Med       Date:  2015-10-30       Impact factor: 2.884

6.  In-Hospital and long term results of primary angioplasty and medical therapy in nonagenarian patients with acute myocardial infarction.

Authors:  Muslum Sahin; Lutfi Ocal; Ali Kemal Kalkan; Alev Kilicgedik; Mehmet Emin Kalkan; Burak Teymen; Ugur Arslantas; Mehmet Muhsin Turkmen
Journal:  J Cardiovasc Thorac Res       Date:  2017-09-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.